Intervention Review

You have free access to this content

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma

  1. Bilgehan Yalçin1,*,
  2. Leontien CM Kremer2,
  3. Huib N Caron2,
  4. Elvira C van Dalen2

Editorial Group: Cochrane Childhood Cancer Group

Published Online: 22 AUG 2013

Assessed as up-to-date: 24 DEC 2012

DOI: 10.1002/14651858.CD006301.pub3


How to Cite

Yalçin B, Kremer LCM, Caron HN, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD006301. DOI: 10.1002/14651858.CD006301.pub3.

Author Information

  1. 1

    Hacettepe University Faculty of Medicine, Pediatric Oncology, Ankara, Turkey

  2. 2

    Emma Children's Hospital / Academic Medical Center, Department of Paediatric Oncology, Amsterdam, Netherlands

*Bilgehan Yalçin, Pediatric Oncology, Hacettepe University Faculty of Medicine, Ankara, 06100, Turkey. yalcinb@hacettepe.edu.tr. bilgehanyalcin@yahoo.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 22 AUG 2013

SEARCH

[Figure 1]
Figure 1. Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.1 Event-free survival without additional follow-up data.
[Figure 2]
Figure 2. Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.2 Event-free survival including additional follow-up data of Matthay 1999.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.3 Overall survival without additional follow-up data.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.4 Overall survival including additional follow-up data of Matthay 1999.
[Figure 5]
Figure 5. Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.5 Adverse effects grade 3 or higher without additional follow-up data.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.6 Adverse effects grade 3 or higher including additional follow-up of Matthay 1999.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Myeloablative therapy versus control, Outcome 1 Event-free survival without additional follow-up data.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Myeloablative therapy versus control, Outcome 2 Event-free survival including additional follow-up data of Matthay 1999.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Myeloablative therapy versus control, Outcome 3 Overall survival without additional follow-up data.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Myeloablative therapy versus control, Outcome 4 Overall survival including additional follow-up data of Matthay 1999.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Myeloablative therapy versus control, Outcome 5 Adverse effects grade 3 or higher without additional follow-up data.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Myeloablative therapy versus control, Outcome 6 Adverse effects grade 3 or higher including additional follow-up of Matthay 1999.